Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 31, 2006Journal of Clinical Oncology

Predictive Factors for Interstitial Lung Disease, Antitumor Response, and Survival in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMasahiko AndoNagoya University HospitalIOIsamu OkamotoKyushu University HospitalNYNobuyuki YamamotoWakayama Medical University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Ando et al. (2006) studied this question.

synapsesocial.com/papers/6a153fb7814bf8ec9a4e4c24https://doi.org/10.1200/jco.2005.04.9866
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Expression of Transforming Growth Factor-α and Epidermal Growth Factor Receptor is Increased Following Bleomycin-Induced Lung Injury in Rats1994 · 143 citations
  2. 2United States Food and Drug Administration Drug Approval Summary2004 · 502 citations
  3. 3Attenuation of acute lung injury in transgenic mice expressing human transforming growth factor-α1999 · 34 citations
  4. 4Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 12004 · 1,725 citations
  5. 5Amplification and Enhanced Expression of the Epidermal Growth Factor Receptor Gene in A431 Human Carcinoma Cells1984 · 408 citations